Chemotherapy with bevacizumab for metastatic colorectal cancer: A retrospective review of 181 Japanese patients

International Journal of Clinical Oncology

Volumn 18, Issue 4, 2013, Pages 689-695

  Saito, Seiya ^a   Hayashi, Naoko ^a   Sato, Nobutaka ^a   Iwatsuki, Masaaki ^a   Baba, Yoshifumi ^a   Sakamoto, Yasuo ^a   Miyamoto, Yuji ^a   Watanabe, Masayuki ^a   Yoshida, Minoru ^b   Sakai, Kenji ^c   Katsumori, Takashi ^d   Katahuchi, Shigeru ^e   Shigaki, Nobuyuki ^f   Yamada, Kazutaka ^g   Kimura, Masami ^h   Tanigawa, Tomio ⁱ   Takano, Sadamu ^j   Kuramoto, Masafumi ^k   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^c SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^d Arao Municipal Hospital   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^f KUMAMOTO CITY HOSPITAL   (Japan)

^g TAKANO HOSPITAL   (Japan)

^h Health Insurance Hitoyoshi General Hospital   (Japan)

ⁱ Minamata City General Hospital and Medical Center   (Japan)

^j Kumamoto Central Hospital   (Japan)

^k Yatsushiro Social Insurance General Hospital   (Japan)

more..

Author keywords

Bevacizumab; Metastatic colorectal cancer; Target therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANOREXIA; BLEEDING; BLOOD CLOTTING DISORDER; CANCER GROWTH; CANCER INCIDENCE; CAUSE OF DEATH; CLINICAL PRACTICE; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPAN; JAPANESE; LIVER DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; MOUTH ULCER; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPERTENSION; INTESTINAL PERFORATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84882571486     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0426-4     Document Type: Review

References (25)

1. Kotake K, Honjo S, Sugihara K et al (2003) Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 46(10 Suppl):S32-S43
2. Muto T, Kotake K, Koyama Y (2001) Colorectal cancer statistics in Japan: data from JSCCR registration, 1974-1993. Int J Clin Oncol 6(4):171-176
3. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186
4. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15-18
5. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77(7):527-543
6. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145-147
7. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7(9):987-989
8. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
9. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013-2019
10. Doi T, Boku N, Kato K et al. (2010) Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 40(10):913-920
11. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1):60-65
12. Tamiya A, Yamazaki K, Boku N et al (2009) Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol 14(6):513-517
13. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842-1847
14. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427-434
15. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539-1544
16. Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16):3697-3705
17. Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326-5334
18. Van Cutsem E, M Michael, S Berry (2007) Preliminary safety and efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and capecitabine for mCRC: first-BEAT trial. Gastrointestinal Cancer Symposium (abstract #346)
19. Flynn P, MM Sugrue, DM Purdie (2008) Serious bleeding events are umcommon in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: results from the BRiTE observational Cohort Study. Gastrointestinal Cancer Symposium (abstract #346)
20. Kozloff M, J Hainsworth, S Badarinath (2007) Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer treated with bevacizumab (BV) plus chemotherapy. Gastrointestinal Cancer Symposium (abstract #364)
21. Sugrue MM, M Kozloff, J Hainsworth (2007) Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: result from the BRiTE registry. Gastrointestinal Cancer Symposium (abstract #345)
22. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10(6):559-568
23. Hedrick E, M Kozloff, J Hainsworth (2006) Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US(BRiTE). ASCO Annual Meeting (abstract #3536), Atlanta, USA
24. Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14(6):1860-1869
25. Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105(1):3-6